Protein Treatment, GRF6019, Seen to Help Maintain Cognition in Alzheimer’s Patients in Phase 2 Trial

Protein Treatment, GRF6019, Seen to Help Maintain Cognition in Alzheimer’s Patients in Phase 2 Trial
Alkahest’s experimental blood-derived protein GRF6019 helps maintain cognition and function in mild to moderate Alzheimer’s disease patients, results of a six-month Phase 2 clinical trial show. “These top-line results indicate a potential benefit of this plasma protein fraction in slowing the progression of cognitive decline in patients with mild to moderate Alzheimer’s disease,” Karoly Nikolich, the chief executive officer of Alkahest, said in a press release. Proteins found in the circulatory system were previously shown to alter motor and cognitive function. GRF6019 is a blood plasma-derived protein developed by Alkahest, in collaboration with Grifols, to treat neurodegenerative disorders. In animal models, treatment with GRF6019 increased the number of neurons and improved age-related problems in learning and memory, while halting inflammation. The Phase 2 trial (NCT03520998) assessed the safety, tolerability, and efficacy of GRF6019. The study enrolled 40 patients with mild to moderate Alzheimer’s disease, who were randomized to receive one of two doses of GRF6019 — a high (100 mL) or a low (250 mL) dose. The therapy was given once a day, directly into the vein, for five conse
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *